The third Plenary Session will feature speakers who are harnessing the power of artificial intelligence (AI) to augment approaches to complex cancer research.

A three-part series will offer a glimpse at 12 innovative therapeutics that are being publicly disclosed for the very first time and may soon reshape the oncology landscape.

Researchers working to overcome challenges with chimeric antigen receptor (CAR) T-cell therapies will speak during a Special Session jointly organized by the AACR and the American Society of Clinical Oncology (ASCO).

A Special Session jointly organized by the AACR and the Japanese Cancer Association (JCA) will examine some of the crucial questions surrounding the development of lung cancer in never-smokers and why this is such an urgent area for research.

Don’t miss the first two Clinical Trials Minisymposia, the Discovery Science Plenary, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.

Sunday’s Plenary Session will examine groundbreaking research across the cancer research continuum, from mechanistic insights to therapeutics to patient outcomes.

Multiple sessions will discuss studies powered by the publicly accessible AACR Project GENIE® pancancer registry and highlight its impact on advancing cancer research.

More than 30 oral and poster presentations at the meeting will be simultaneously published as articles in AACR journals, reflecting the high number of laudable abstracts submitted for presentation.

AACR President Lillian L. Siu, MD, FAACR, will share lessons gained from more than three decades of treating head and neck cancer and convene a panel of leading experts on cancer prevention.

In addition to the director’s address, 10 other sessions at the Annual Meeting will feature representatives from the National Cancer Institute (NCI) and National Institutes of Health (NIH) and provide information about funding opportunities and other resources.